Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 18, 2020 01:00 ET | Source: Vivet Therapeutics

Vivet Therapeutics y Pfizer Inc reciben autorización de la FDA para iniciar GATEWAY, ensayo clínico de fase 1/2 con VTX-801, la terapia génica de Vivet para la enfermedad de Wilson

Vivet Therapeutics y Pfizer Inc reciben...
November 18, 2020 01:00 ET | Source: Vivet Therapeutics

Vivet Therapeutics et Pfizer Inc. annoncent l’autorisation de la FDA de commencer l’étude de Phase 1/2 du VTX-801, GATEWAY, la thérapie génique expérimentale de Vivet pour la maladie de Wilson

...
November 18, 2020 01:00 ET | Source: Vivet Therapeutics

Vivet Therapeutics and Pfizer Inc. Announce FDA Authorization to Proceed with GATEWAY, the Phase 1/2 Study for VTX-801, Vivet’s Investigational Gene Therapy for Wilson Disease

Vivet Therapeutics and Pfizer...